Read more

December 12, 2019
1 min read
Save

Readings with handheld autorefractor comparable to subjective refraction

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers found that the QuickSee Handheld wavefront autorefractor provided visual acuity results that were in “excellent agreement” with subjective refraction.

The handheld device may be an affordable option to increase access to eye care in developing countries, they said in a study published in Optometry and Vision Science.

“This study aims to present the first clinical validation of the commercial version of a low-cost handheld autorefractor technology,” researcher Marcos Rubio, MSc, Universidad Autónoma de Madrid, and colleagues wrote.

The study consisted of a cohort of 54 patients ranging from 22 to 65 years of age with -7.25 D to 4.25 D in spherical equivalent refraction. Agreement between the refraction methods using standard clinical procedures with a subjective refraction (SR) and the handheld autorefractor was evaluated.

Researchers considered the first measurement by the autorefractor for analysis of the agreement with SR instead of using an average of several measurements. Agreement with SR was shown to be significantly stronger with the handheld autorefractor in 87% of the eyes evaluated.

“QuickSee has already measured more than 2 million eyes,” Shivang R. Dave, PhD, PlenOptika CEO, said in a company press release from. “But the World Health Organization estimates over a billion people suffer from poor vision due to uncorrected refractive error. Our design goal from the beginning was to lower the barriers to high quality vision care. Demonstrating QuickSee’s ability to do this is a major milestone for us.”

According to the press release, QuickSee is in clinical use in the U.S. and has been expanded in global health missions in countries in North America, Africa, and the Indian subcontinent. – by Erin T. Welsh


Disclosure: Rubio reports funding through grant agreements between Universidad Autónoma de Madrid and PlenOptika Inc. Please see the full study for all other authors’ relevant financial disclosures.